Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Academic Article uri icon

Overview

abstract

  • BACKGROUND: This prospective placebo-controlled trial was designed to determine whether intravenous immune globulin (IVIG) improves left ventricular ejection fraction (LVEF) in adults with recent onset of idiopathic dilated cardiomyopathy or myocarditis. METHODS AND RESULTS: Sixty-two patients (37 men, 25 women; mean age +/-SD 43.0+/-12.3 years) with recent onset (/=0.10 from study entry, and 20 (36%) of 56 normalized their ejection fraction (>/=0.50). The transplant-free survival rate was 92% at 1 year and 88% at 2 years. CONCLUSIONS: These results suggest that for patients with recent-onset dilated cardiomyopathy, IVIG does not augment the improvement in LVEF. However, in this overall cohort, LVEF improved significantly during follow-up, and the short-term prognosis remains favorable.

publication date

  • May 8, 2001

Research

keywords

  • Cardiomyopathy, Dilated
  • Immunization, Passive
  • Immunoglobulins, Intravenous

Identity

Scopus Document Identifier

  • 0006518635

Digital Object Identifier (DOI)

  • 10.1161/01.cir.103.18.2254

PubMed ID

  • 11342473

Additional Document Info

volume

  • 103

issue

  • 18